LEXINGTON, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.
In addition, data will be presented from clinical studies of Erivedge®, a first-in-class drug approved for the treatment of patients with advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.
Additional information on the presentations can be found below and abstracts can be accessed at www.asco.org.
|CUDC-907 Poster Presentation:|
|Date/Time:||Monday, June 6, 8 AM – 11:30 AM CDT|
|Presentation Title:||Phase 2, open-label study of CUDC-907 with and without rituximab|
in patients with relapsed/refractory MYC-altered diffuse large B cell
|Erivedge® Poster Presentations:|
|Date/Time:||Poster Session: Saturday, June 4, 1 PM – 4:30 PM CDT|
|Poster Discussion Session: Saturday, June 4, 4:45 PM – 6 PM CDT|
|Presentation Title:||Mikie: A randomized, double-blinded, regimen-controlled, phase 2|
study to assess the efficacy and safety of two different vismodegib
(VISMO) regimens in patients (pts) with multiple basal cell
|Date/Time:||Saturday, June 4, 1 PM – 4:30 PM CDT|
|Presentation Title:||Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in|
advanced basal cell carcinoma (aBCC): STEVIE study primary
analysis in 1215 patients (pts)
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exercised options to exclusively license oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
CONTACT: For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 email@example.com Media Contact David Schull Russo Partners (212) 845-4271 firstname.lastname@example.org